MCID: CLR109
MIFTS: 54

Colorectal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma 12 14
Adenocarcinoma of Large Intestine 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050861
UMLS 69 C1319315

Summaries for Colorectal Adenocarcinoma

Disease Ontology : 12 A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to colorectal adenoma and mucinous bronchioloalveolar adenocarcinoma. An important gene associated with Colorectal Adenocarcinoma is FABP6 (Fatty Acid Binding Protein 6), and among its related pathways/superpathways are Developmental Biology and fMLP Pathway. The drugs Bevacizumab and Iron have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 300)
# Related Disease Score Top Affiliating Genes
1 colorectal adenoma 30.7 CTNNB1 HRAS KRAS MLH1 MSH2 TP53
2 mucinous bronchioloalveolar adenocarcinoma 30.2 CDX2 KRT20 KRT7
3 bladder adenocarcinoma 30.2 CDX2 KRT20 KRT7
4 villous adenoma 30.0 BRAF CDX2 KRAS KRT20
5 adenocarcinoma 29.8 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
6 oral squamous cell carcinoma 29.1 CDH1 CTNNB1 EGFR HRAS TP53
7 squamous cell carcinoma 29.0 BRAF CDH1 CEACAM5 EGFR HRAS KRT7
8 small intestinal adenocarcinoma 28.9 BRAF CDX2 CTNNB1 EGFR KRAS MUC2
9 adenoma 28.8 BRAF CTNNB1 KRAS KRT7 MLH1 MSH2
10 familial adenomatous polyposis 28.8 CDH1 CTNNB1 KRAS MLH1 MSH2 TP53
11 lynch syndrome 28.7 BRAF CTNNB1 KRAS MLH1 MSH2 MUC2
12 mucinous adenocarcinoma 28.6 CDX2 EGFR KRAS KRT20 KRT7 MLH1
13 gastric adenocarcinoma 28.5 CDH1 CDX2 CEACAM5 CTNNB1 HRAS KRT20
14 esophageal cancer 28.3 CDH1 CDX2 CEACAM5 CTNNB1 EGFR HRAS
15 hepatocellular carcinoma 28.3 CDH1 CEACAM5 CTNNB1 EGFR HRAS KRAS
16 colorectal cancer 26.2 AURKA BRAF CDH1 CDX2 CEACAM5 CTNNB1
17 nevus of ota 10.6 BRAF TP53
18 cystic basal cell carcinoma 10.6 KRT20 KRT7
19 hyperplastic polyposis syndrome 10.6 BRAF KRAS TP53
20 brain ependymoma 10.6 EGFR TP53
21 cerebellar astrocytoma 10.5 BRAF TP53
22 mature teratoma 10.5 BRAF KRAS TP53
23 mucoepidermoid esophageal carcinoma 10.5 CEACAM5 TP53
24 eccrine sweat gland neoplasm 10.5 KRT20 KRT7 TP53
25 benign breast adenomyoepithelioma 10.5 EGFR KRT7
26 seminal vesicle adenocarcinoma 10.5 KRT20 KRT7
27 papillary serous adenocarcinoma 10.5 KRT20 KRT7 TP53
28 transverse colon cancer 10.5 KRT20 KRT7
29 glycogen-rich clear cell breast carcinoma 10.5 KRT20 KRT7 TP53
30 cutaneous mucoepidermoid carcinoma 10.5 CEACAM5 KRT7
31 anal gland adenocarcinoma 10.5 CEACAM5 KRT7
32 ovarian large-cell neuroendocrine carcinoma 10.5 KRT20 KRT7
33 anal canal adenocarcinoma 10.5 CDX2 KRAS KRT7
34 vaginal benign neoplasm 10.5 CDX2 KRT20 KRT7
35 vaginal adenoma 10.5 CDX2 KRT20 KRT7
36 vaginal tubulovillous adenoma 10.5 CDX2 KRT20 KRT7
37 glandular cystitis 10.5 CDX2 KRT20 KRT7
38 ovarian clear cell carcinoma 10.5 KRAS KRT7 TP53
39 tumor suppressor gene on chromosome 11 10.5 BRAF EGFR KRAS
40 inverted papilloma 10.5 KRT20 KRT7 TP53
41 anus adenocarcinoma 10.5 CEACAM5 KRT7
42 intracranial chondrosarcoma 10.5 CEACAM5 TP53
43 jejunal adenocarcinoma 10.5 CDX2 KRT20 KRT7
44 sweat gland cancer 10.5 KRT20 KRT7 TP53
45 chronic cystitis 10.5 CDX2 KRT20 KRT7
46 clear cell adenocarcinoma 10.5 KRT20 KRT7 TP53
47 anus cancer 10.5 CDX2 KRAS KRT7
48 pleomorphic carcinoma 10.5 EGFR KRT7 TP53
49 malignant spiradenoma 10.5 CEACAM5 KRT7 TP53
50 pulmonary blastoma 10.5 EGFR KRAS TP53

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:



Diseases related to Colorectal Adenocarcinoma

Symptoms & Phenotypes for Colorectal Adenocarcinoma

GenomeRNAi Phenotypes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.82 KRAS HRAS PIM2 BRAF EGFR AURKA
2 Decreased viability GR00106-A-0 10.82 KRAS
3 Decreased viability GR00173-A 10.82 CDK8
4 Decreased viability GR00221-A-1 10.82 KRAS HRAS PIM2 EGFR CDH1 AURKA
5 Decreased viability GR00221-A-2 10.82 KRAS HRAS AURKA CDK8
6 Decreased viability GR00221-A-3 10.82 HRAS
7 Decreased viability GR00221-A-4 10.82 BRAF EGFR AURKA CDK8
8 Decreased viability GR00231-A 10.82 AURKA
9 Decreased viability GR00301-A 10.82 KRAS MSH2 PIM2 BRAF CDH1 CDK8
10 Decreased viability GR00381-A-1 10.82 KRAS BRAF
11 Decreased cell migration GR00055-A-1 9.97 HRAS PIM2 KRAS CTNNB1 EGFR AURKA
12 Decreased viability in esophageal squamous lineage GR00235-A 9.9 FABP6 KRAS KRT7 MLH1 HRAS TP53
13 Decreased cella89culturea89derived Hepatitis C virus (HCVcc GR00234-A-2 9.5 EGFR BRAF CDK8
14 Increased cell migration GR00055-A-3 9.43 KRAS HRAS CTNNB1 BRAF EGFR AURKA
15 Increased cell viability after pRB stimulation GR00230-A-1 8.92 EGFR PIM2 CDK8 AURKA

MGI Mouse Phenotypes related to Colorectal Adenocarcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 CDX2 AURKA CTNNB1 BRAF EGFR CDH1
2 digestive/alimentary MP:0005381 10.17 CTNNB1 BRAF EGFR CDH1 HRAS CDX2
3 homeostasis/metabolism MP:0005376 10.13 CDX2 CTNNB1 BRAF EGFR FABP6 CDH1
4 endocrine/exocrine gland MP:0005379 10.07 CTNNB1 BRAF EGFR CDH1 HRAS CDX2
5 embryo MP:0005380 10.06 CDX2 AURKA CTNNB1 BRAF EGFR CDH1
6 mortality/aging MP:0010768 10 AURKA CTNNB1 BRAF EGFR CDH1 FGFBP1
7 integument MP:0010771 9.91 CTNNB1 BRAF EGFR CDH1 HRAS KRAS
8 neoplasm MP:0002006 9.73 AURKA CTNNB1 BRAF EGFR CDH1 HRAS
9 pigmentation MP:0001186 9.02 CTNNB1 BRAF EGFR KRAS TP53

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
2
Iron Approved Phase 4 7439-89-6 23925
3 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
4 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Ferric Compounds Phase 4
6 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
7 Hepcidins Phase 4
8 Iron Supplement Nutraceutical Phase 4
9
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
10
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
11
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
12
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
13
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
14
Nicotine Approved Phase 3 54-11-5 89594 942
15
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
17
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
18 Antidotes Phase 3,Phase 2,Phase 1
19 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
20 Antimetabolites Phase 3,Phase 2,Phase 1
21 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
22 Protective Agents Phase 3,Phase 2,Phase 1
23 Calcium, Dietary Phase 3,Phase 2
24 Micronutrients Phase 3,Phase 2,Phase 1
25 Trace Elements Phase 3,Phase 2,Phase 1
26 Vitamin B Complex Phase 3,Phase 2,Phase 1
27 Vitamins Phase 3,Phase 2,Phase 1
28 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
29 Pharmaceutical Solutions Phase 3,Phase 2
30 Immunoglobulins Phase 3,Phase 2,Phase 1
31 Liver Extracts Phase 3,Phase 2,Phase 1
32 Antibodies Phase 3,Phase 2,Phase 1
33 Mitogens Phase 3,Phase 2,Phase 1
34 Mitomycins Phase 2, Phase 3
35 Endothelial Growth Factors Phase 3,Phase 2
36 Bone Density Conservation Agents Phase 3,Phase 2
37 Formyltetrahydrofolates Phase 3
38 Tetrahydrofolates Phase 3
39 Folate Nutraceutical Phase 3,Phase 2,Phase 1
40 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
41
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
42
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
43
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
44
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
45
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
46
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
47
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
48
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
49
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
50
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 114)

# Name Status NCT ID Phase Drugs
1 A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma Completed NCT00097578 Phase 4
2 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
3 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
4 Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases Completed NCT00265356 Phase 3
5 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
6 Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM Recruiting NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
7 Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Recruiting NCT02997228 Phase 3 Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
8 Perioperative Systemic Therapy and Surgery Versus Surgery Alone for Resectable Colorectal Peritoneal Metastases. Recruiting NCT02758951 Phase 2, Phase 3 Perioperative systemic therapy
9 A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) Active, not recruiting NCT02788279 Phase 3 Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
10 Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT) Active, not recruiting NCT02390947 Phase 3 Famitinib;Placebo
11 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Not yet recruiting NCT03300609 Phase 3 Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
12 Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma Unknown status NCT01552967 Phase 2 Capecitabine
13 Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. Unknown status NCT01067053 Phase 2 bevacizumab, capecitabine, oxaliplatin
14 Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma Unknown status NCT00075556 Phase 2 capecitabine
15 Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00544011 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride
16 Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Unknown status NCT00104689 Phase 2 capecitabine;oxaliplatin
17 Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
18 Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma Completed NCT00034190 Phase 2 S-8184 Paclitaxel Injectable Emulsion
19 Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) Completed NCT01900717 Phase 2 LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
20 Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma Completed NCT00168155 Phase 2 perioperative chemotherapy
21 Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma. Completed NCT02181465 Phase 2
22 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma Completed NCT00574171 Phase 2 lapatinib;Capecitabine
23 Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma Completed NCT01479465 Phase 2 Simtuzumab;FOLFIRI;Placebo to match simtuzumab
24 DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma Completed NCT00080834 Phase 2 DJ-927
25 Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy Completed NCT00419159 Phase 2 Everolimus (RAD001)
26 Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus Completed NCT00597506 Phase 2 Bevacizumab;Everolimus
27 Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Completed NCT00165217 Phase 2 Capecitabine;Thalidomide
28 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
29 Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer Completed NCT00003220 Phase 2 bryostatin 1
30 Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer Completed NCT00025350 Phase 2 gefitinib
31 Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Completed NCT00890305 Phase 2 CT-011;FOLFOX
32 Safety and Efficacy of a Genetically Engineered Herpes Simplex Virus NV1020 to Treat Colorectal Cancer Metastatic to Liver Completed NCT00149396 Phase 1, Phase 2 NV1020
33 1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer Completed NCT01417494 Phase 2 Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
34 Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer Completed NCT00123851 Phase 2 Tarceva (OSI-774);Capecitabine;Oxaliplatin
35 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib Completed NCT00582660 Phase 2 Celecoxib;Placebo
36 Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy Completed NCT01225744 Phase 2 Cetuximab;Irinotecan;Oxaliplatin;UFT
37 Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed Completed NCT00259844 Phase 2
38 Azacitidine and CAPOX in Metastatic Colorectal Cancer Completed NCT01193517 Phase 1, Phase 2 Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
39 Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma . Recruiting NCT02788006 Phase 2 Regorafenib 160 mg
40 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
41 Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver Recruiting NCT03069950 Phase 2 Floxuridine (FUDR);Irinotecan (CPT-11);FLUOROURACIL;PANITUMUMAB;DEXAMETHASONE;Leucovorin
42 Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA) Recruiting NCT02738606 Phase 2 Chemotherapy
43 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer Recruiting NCT01053013 Phase 2
44 A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Recruiting NCT02599324 Phase 1, Phase 2 ibrutinib;everolimus;docetaxel;paclitaxel;cetuximab
45 Regorafenib in Metastatic Colorectal Cancer Recruiting NCT02466009 Phase 2 Regorafenib
46 Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors Recruiting NCT01876511 Phase 2 MK-3475;MK-3475
47 A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Recruiting NCT03206073 Phase 1, Phase 2 Durvalumab;Tremelimumab
48 Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies Recruiting NCT02638909 Phase 2 ceritinib
49 TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting NCT03368963 Phase 1, Phase 2 Nanoliposomal Irinotecan;Trifluridine and Tipiracil Hydrochloride
50 Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer Recruiting NCT03043313 Phase 2 Tucatinib

Search NIH Clinical Center for Colorectal Adenocarcinoma

Genetic Tests for Colorectal Adenocarcinoma

Anatomical Context for Colorectal Adenocarcinoma

MalaCards organs/tissues related to Colorectal Adenocarcinoma:

38
Liver, Colon, Lung, Endothelial, Bone, Kidney, Prostate

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 599)
# Title Authors Year
1
MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma. ( 29193645 )
2018
2
Investigating the association between African spontaneously fermented dairy products, faecal carriage of Streptococcus infantarius subsp. infantarius and colorectal adenocarcinoma in Kenya. ( 29079186 )
2018
3
Expression of GAEC1 mRNA and protein and its association with clinical and pathological parameters of patients with colorectal adenocarcinoma. ( 29337242 )
2018
4
Nuclear expression of claudin-3 in human colorectal adenocarcinoma cell lines and tissues. ( 29285188 )
2018
5
Ultrastructure of colorectal adenocarcinoma and peritumoral tissue in untreated patients. ( 29419351 )
2018
6
Predictors for local recurrence and distant metastasis of mucinous colorectal adenocarcinoma. ( 29361368 )
2018
7
Decreased Expression of the Polarity Regulatory PAR Complex Predicts Poor Prognosis of the Patients with Colorectal Adenocarcinoma. ( 29220829 )
2018
8
Triple primary malignancies in a patient with colorectal adenocarcinoma: A case report. ( 29216528 )
2018
9
Collision tumor consisting of a colorectal adenocarcinoma and dissemination of a gastric adenocarcinoma. ( 29326826 )
2018
10
Hepatobiliary and Pancreatic: Hepatic nodules in a patient with familial adenomatous polyposis and colorectal adenocarcinoma. ( 29284077 )
2018
11
The Smad4/PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma. ( 29056035 )
2018
12
Human epidermal growth factor (Her-2) in gastric and colorectal adenocarcinoma. ( 28770892 )
2017
13
Two case reports: Colorectal adenocarcinoma in children. ( 29145239 )
2017
14
Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma. ( 28187432 )
2017
15
6-shogaol induces autophagic cell death then triggered apoptosis in colorectal adenocarcinoma HT-29 cells. ( 28641163 )
2017
16
An Unusual Case of Colorectal Adenocarcinoma Presenting as an Anterior Mediastinal Mass. ( 29169975 )
2017
17
Hierarchical cluster analysis and chemical characterisation of Myrtus communis L. essential oil from Yemen region and its antimicrobial, antioxidant and anti-colorectal adenocarcinoma properties. ( 28068844 )
2017
18
B2 adrenergic receptors and morphological changes of the enteric nervous system in colorectal adenocarcinoma. ( 28275305 )
2017
19
Aldolase B Overexpression is Associated with Poor Prognosis and Promotes Tumor Progression by Epithelial-Mesenchymal Transition in Colorectal Adenocarcinoma. ( 28558381 )
2017
20
Does tumor size have its prognostic role in colorectal cancer? Re-evaluating its value in colorectal adenocarcinoma with different macroscopic growth pattern. ( 28760707 )
2017
21
Gastrointestinal stromal tumor with synchronous colorectal adenocarcinoma. ( 28655207 )
2017
22
Evaluation of safety, feasibility and the long-term outcomes of colorectomy for colorectal adenocarcinoma in patients older than 80 years of age. ( 29046791 )
2017
23
Phosphorylated Protein Kinase C (Zeta/Lambda) Expression in Colorectal Adenocarcinoma and Its Correlation with Clinicopathologic Characteristics and Prognosis. ( 29158810 )
2017
24
Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: Clinicopathological significance. ( 28677737 )
2017
25
Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissues. ( 28088229 )
2017
26
Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population. ( 29308089 )
2017
27
Late recurrence of colorectal adenocarcinoma as a renal tumour by direct spread via the ureter. ( 28588649 )
2017
28
P16ink4a Subcellular Expression Patterns in Colorectal Adenocarcinoma, Adenoma and Non-Neoplastic Tissue Samples ( 29172278 )
2017
29
Clinical and Histopathologic Features of Colorectal Adenocarcinoma in Crohn's Disease. ( 28654553 )
2017
30
miRNA biogenesis-associated RNase III nucleases Drosha and Dicer are upregulated in colorectal adenocarcinoma. ( 28943952 )
2017
31
Migration of mitochondrial DNA in the nuclear genome of colorectal adenocarcinoma. ( 28356157 )
2017
32
miR-34a overexpression predicts poor prognostic outcome in colorectal adenocarcinoma, independently of clinicopathological factors with established prognostic value. ( 28624481 )
2017
33
Comparison of gene expression profiles of gingival carcinoma Ca9-22 cells and colorectal adenocarcinoma HT-29 cells to identify potentially important mediators of SLPI-induced cell migration. ( 28637988 )
2017
34
KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. ( 28188750 )
2017
35
Salvia fruticosa Modulates mRNA Expressions and Activity Levels of Xenobiotic Metabolizing CYP1A2, CYP2E1, NQO1, GPx, and GST Enzymes in Human Colorectal Adenocarcinoma HT-29 Cells. ( 28718679 )
2017
36
Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( 28819759 )
2017
37
Doxorubicin-Wrapped Zinc Oxide Nanoclusters for the Therapy of Colorectal Adenocarcinoma. ( 29143771 )
2017
38
Glandular Morphometrics for Objective Grading of Colorectal Adenocarcinoma Histology Images. ( 29203775 )
2017
39
Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing. ( 27863258 )
2017
40
Effects of proton beam irradiation on mitochondrial biogenesis in a human colorectal adenocarcinoma cell line. ( 28713989 )
2017
41
Implications of inflammation and remodeling of the enteric glial cells in colorectal adenocarcinoma. ( 28730232 )
2017
42
Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29. ( 28560404 )
2017
43
Expression of pattern recognition receptor genes and mortality in patients with colorectal adenocarcinoma. ( 28533893 )
2017
44
Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/I^-catenin signaling pathway in human colorectal adenocarcinoma. ( 28259923 )
2017
45
Eradication of HT-29 colorectal adenocarcinoma cells by controlled photorelease of CO from a CO-releasing polymer (photoCORP-1) triggered by visible light through an optical fiber-based device. ( 28866022 )
2017
46
FGFR2 Amplification in Colorectal Adenocarcinoma. ( 28835367 )
2017
47
Aurora Kinase A Is a Prognostic Marker in Colorectal Adenocarcinoma. ( 28013532 )
2017
48
Racial Disparities in Clinical Presentation and Survival Times Among Young-Onset Colorectal Adenocarcinoma. ( 28631085 )
2017
49
Knockdown of PARP6 or survivin promotes cell apoptosis and inhibits cell invasion of colorectal adenocarcinoma cells. ( 28260087 )
2017
50
Cutaneous metastasis to the scalp as the primary presentation of colorectal adenocarcinoma. ( 29447644 )
2017

Variations for Colorectal Adenocarcinoma

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 BRAF CDK8 CTNNB1 EGFR HRAS KRAS
2
Show member pathways
13.01 BRAF CDH1 CTNNB1 HRAS KRAS TP53
3
Show member pathways
12.95 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
4 12.77 BRAF EGFR HRAS KRAS TP53
5
Show member pathways
12.69 BRAF EGFR HRAS KRAS TP53
6
Show member pathways
12.69 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
7 12.68 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
8
Show member pathways
12.67 BRAF CDH1 CTNNB1 HRAS KRAS TP53
9
Show member pathways
12.59 BRAF EGFR HRAS KRAS TP53
10
Show member pathways
12.57 CTNNB1 EGFR HRAS KRAS MSH2 TP53
11 12.52 AURKA CDK8 MLH1 MSH2 TP53
12
Show member pathways
12.52 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
13
Show member pathways
12.5 BRAF EGFR HRAS KRAS TP53
14
Show member pathways
12.47 BRAF EGFR HRAS KRAS TP53
15
Show member pathways
12.46 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
16
Show member pathways
12.42 CTNNB1 EGFR HRAS KRAS TP53
17
Show member pathways
12.41 BRAF CTNNB1 HRAS KRAS
18
Show member pathways
12.38 CTNNB1 HRAS KRAS TP53
19
Show member pathways
12.29 BRAF FGFBP1 HRAS KRAS
20
Show member pathways
12.28 BRAF HRAS KRAS TP53
21
Show member pathways
12.28 BRAF CDH1 CTNNB1 HRAS
22 12.26 BRAF CTNNB1 EGFR HRAS KRAS TP53
23
Show member pathways
12.23 BRAF EGFR HRAS KRAS TP53
24
Show member pathways
12.2 BRAF HRAS KRAS TP53
25
Show member pathways
12.16 BRAF HRAS KRAS TP53
26 12.15 AURKA BRAF EGFR HRAS KRAS
27
Show member pathways
12.11 BRAF EGFR HRAS KRAS TP53
28
Show member pathways
12.1 BRAF EGFR HRAS KRAS
29 12.08 EGFR MLH1 MSH2 TP53
30 12.08 KRAS MLH1 MSH2 TP53
31
Show member pathways
12.07 EGFR HRAS KRAS TP53
32 12.03 BRAF EGFR HRAS KRAS TP53
33 12.02 CDH1 CTNNB1 HRAS KRAS
34 11.98 CTNNB1 HRAS KRAS TP53
35 11.97 CTNNB1 HRAS KRAS TP53
36 11.93 BRAF CTNNB1 EGFR HRAS KRAS TP53
37
Show member pathways
11.82 BRAF HRAS KRAS
38 11.79 BRAF KRAS TP53
39 11.78 BRAF CDH1 CTNNB1 EGFR KRAS MLH1
40 11.75 MLH1 MSH2 TP53
41 11.74 CDH1 CTNNB1 EGFR
42 11.69 HRAS KRAS TP53
43
Show member pathways
11.69 BRAF HRAS KRAS
44 11.66 EGFR HRAS KRAS TP53
45 11.66 BRAF CDH1 EGFR HRAS KRAS TP53
46 11.65 BRAF HRAS KRAS
47 11.62 EGFR HRAS KRAS
48 11.54 EGFR HRAS KRAS
49
Show member pathways
11.45 MLH1 MSH2 TP53
50 11.44 CDH1 CTNNB1 EGFR

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 catenin complex GO:0016342 9.16 CDH1 CTNNB1
2 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
3 mismatch repair complex GO:0032300 8.62 MLH1 MSH2

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 BRAF CTNNB1 HRAS KRAS TP53
2 cell proliferation GO:0008283 9.91 CTNNB1 EGFR HRAS PIM2 TP53
3 positive regulation of transcription, DNA-templated GO:0045893 9.91 CDH1 CDX2 CTNNB1 EGFR PIM2 TP53
4 negative regulation of apoptotic process GO:0043066 9.8 AURKA BRAF CEACAM5 EGFR PIM2 TP53
5 Ras protein signal transduction GO:0007265 9.77 HRAS KRAS TP53
6 cellular response to drug GO:0035690 9.74 BRAF EGFR TP53
7 positive regulation of MAP kinase activity GO:0043406 9.73 EGFR HRAS KRAS
8 positive regulation of cell proliferation GO:0008284 9.73 CDX2 CTNNB1 EGFR FGFBP1 HRAS KRAS
9 epidermal growth factor receptor signaling pathway GO:0007173 9.72 EGFR HRAS KRAS
10 negative regulation of neuron apoptotic process GO:0043524 9.71 BRAF HRAS KRAS MSH2
11 entry of bacterium into host cell GO:0035635 9.61 CDH1 CTNNB1
12 response to UV-B GO:0010224 9.6 MSH2 TP53
13 positive regulation of isotype switching to IgG isotypes GO:0048304 9.58 MLH1 MSH2
14 response to isolation stress GO:0035900 9.58 HRAS KRAS
15 positive regulation of fibroblast growth factor receptor signaling pathway GO:0045743 9.54 CTNNB1 FGFBP1
16 ERBB2 signaling pathway GO:0038128 9.54 EGFR HRAS KRAS
17 positive regulation of isotype switching to IgA isotypes GO:0048298 9.49 MLH1 MSH2
18 somatic recombination of immunoglobulin gene segments GO:0016447 9.48 MLH1 MSH2
19 cellular response to indole-3-methanol GO:0071681 9.46 CDH1 CTNNB1
20 negative regulation of cell proliferation GO:0008285 9.43 CTNNB1 FABP6 FGFBP1 HRAS PIM2 TP53
21 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.16 MLH1 MSH2
22 anterior/posterior axis specification GO:0009948 8.8 AURKA CDX2 CTNNB1

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.86 AURKA BRAF CDK8 EGFR MLH1 MSH2
2 protein kinase binding GO:0019901 9.77 AURKA CTNNB1 EGFR MSH2 TP53
3 protein C-terminus binding GO:0008022 9.62 CTNNB1 HRAS MSH2 TP53
4 protein phosphatase binding GO:0019903 9.58 CTNNB1 EGFR TP53
5 mismatched DNA binding GO:0030983 9.43 MLH1 MSH2
6 double-stranded DNA binding GO:0003690 9.26 CDX2 CTNNB1 EGFR MSH2
7 guanine/thymine mispair binding GO:0032137 9.16 MLH1 MSH2
8 nucleotide binding GO:0000166 9.1 AURKA BRAF EGFR HRAS KRAS PIM2

Sources for Colorectal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....